ALX Oncology Holdings Inc. is a clinical-stage biotechnology company developing immuno-oncology therapies that enhance immune system activity against cancer. Its lead product candidate, evorpacept, is a CD47 blocker evaluated in combination regimens for various solid tumors and blood cancers. An additional pipeline asset targets EGFR with a differentiated antibody-drug conjugate.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -30.8 | — |
| Q2 2025 | 0 | — | -25.9 | — |
| Q3 2025 | 0 | — | -22.1 | — |
| Q4 2025 | 0 | — | -22.9 | — |
| Q1 2026 | 0 | — | -17.9 | — |
| Q2 2026 | 0 | — | -18 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Global Water Resources, Inc. (GWRS), Oaktree Acquisition Corp. III Life Sciences (OACC), Exascale Labs Holdings Inc. Class A Common Stock (XLAB), Soluna Holdings, Inc. (SLNH), Newbury Street II Acquisition Corp (NTWO), AIAI Holdings Corporation (AIAI)